Ellis Kathryn A, Bush Ashley I, Darby David, De Fazio Daniela, Foster Jonathan, Hudson Peter, Lautenschlager Nicola T, Lenzo Nat, Martins Ralph N, Maruff Paul, Masters Colin, Milner Andrew, Pike Kerryn, Rowe Christopher, Savage Greg, Szoeke Cassandra, Taddei Kevin, Villemagne Victor, Woodward Michael, Ames David
Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, St. Vincent's Aged Psychiatry Service, St George's Hospital, Victoria, Australia.
Int Psychogeriatr. 2009 Aug;21(4):672-87. doi: 10.1017/S1041610209009405. Epub 2009 May 27.
The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging aimed to recruit 1000 individuals aged over 60 to assist with prospective research into Alzheimer's disease (AD). This paper describes the recruitment of the cohort and gives information about the study methodology, baseline demography, diagnoses, medical comorbidities, medication use, and cognitive function of the participants.
Volunteers underwent a screening interview, had comprehensive cognitive testing, gave 80 ml of blood, and completed health and lifestyle questionnaires. One quarter of the sample also underwent amyloid PET brain imaging with Pittsburgh compound B (PiB PET) and MRI brain imaging, and a subgroup of 10% had ActiGraph activity monitoring and body composition scanning.
A total of 1166 volunteers were recruited, 54 of whom were excluded from further study due to comorbid disorders which could affect cognition or because of withdrawal of consent. Participants with AD (211) had neuropsychological profiles which were consistent with AD, and were more impaired than participants with mild cognitive impairment (133) or healthy controls (768), who performed within expected norms for age on neuropsychological testing. PiB PET scans were performed on 287 participants, 100 had DEXA scans and 91 participated in ActiGraph monitoring.
The participants comprising the AIBL cohort represent a group of highly motivated and well-characterized individuals who represent a unique resource for the study of AD. They will be reassessed at 18-month intervals in order to determine the predictive utility of various biomarkers, cognitive parameters and lifestyle factors as indicators of AD, and as predictors of future cognitive decline.
澳大利亚影像、生物标志物与生活方式（AIBL）衰老旗舰研究旨在招募1000名60岁以上的个体，以协助对阿尔茨海默病（AD）进行前瞻性研究。本文描述了该队列的招募情况，并提供了有关研究方法、基线人口统计学、诊断、合并症、药物使用以及参与者认知功能的信息。
志愿者接受了筛选访谈，进行了全面的认知测试，提供了80毫升血液，并完成了健康和生活方式问卷。四分之一的样本还接受了匹兹堡化合物B淀粉样蛋白PET脑成像（PiB PET）和MRI脑成像，10%的亚组进行了ActiGraph活动监测和身体成分扫描。
共招募了1166名志愿者，其中54名因可能影响认知的合并症或因撤回同意而被排除在进一步研究之外。患有AD的参与者（211名）具有与AD一致的神经心理学特征，且比患有轻度认知障碍的参与者（133名）或健康对照者（768名）受损更严重，后者在神经心理学测试中的表现符合其年龄的预期标准。对287名参与者进行了PiB PET扫描，100名进行了双能X线吸收法扫描，91名参与了ActiGraph监测。
组成AIBL队列的参与者代表了一组积极性高且特征明确的个体，他们是AD研究的独特资源。将每隔18个月对他们进行重新评估，以确定各种生物标志物、认知参数和生活方式因素作为AD指标以及未来认知衰退预测指标的预测效用。
